Influence of Body Composition on the Perioperative and Survival Outcomes of Renal Cell Carcinoma by Edouard H. Nicaise, Benjamin N. Schmeusser, Yash B. Shah, Mehmet A. Bilen, Kenneth Ogan, Viraj A. Master

Get full text

Recent progress in non-clear cell renal cell carcinoma: biology and therapeutic strategies by Ahmet Yildirim, Marcus W. Moses, Margo Gerke, Yash Jani, Jillian C. Thompson, Umut Akova, Mehmet A. Bilen

Get full text

Overall survival in patients with metastatic castration-sensitive prostate cancer treated with apalutamide versus abiraterone acetate: a head-to-head analysis of real-world patient... by Benjamin Lowentritt, Mehmet A Bilen, Ibrahim Khilfeh, Carmine Rossi, Shawn Du, Frederic Kinkead, Lilian Diaz, Dominic Pilon, Lorie Ellis, Neal D Shore

Association between neutrophil-to-eosinophil ratio and efficacy outcomes with avelumab plus axitinib or sunitinib in patients with advanced renal cell carcinoma: post hoc analyses... by Brian Rini, Mariangela Mariani, Alessandra di Pietro, Paul Nathan, Christian Kollmannsberger, Marc-Oliver Grimm, Martin H Voss, Bradley A McGregor, Mehmet A Bilen, Yoshihiko Tomita, Bo Huang, Robert Amezquita, Matthew Tucker, Yu-Wei Chen

Get full text

A novel preoperative inflammatory marker prognostic score in patients with localized and metastatic renal cell carcinoma by Rishi R. Sekar, Dattatraya Patil, Yoram Baum, Jeffrey Pearl, Anna Bausum, Mehmet A. Bilen, Omer Kucuk, Wayne B. Harris, Bradley C. Carthon, Mehrdad Alemozaffar, Christopher P. Filson, John G. Pattaras, Peter T. Nieh, Kenneth Ogan, Viraj A. Master

Get full text

Impact of immunotherapy time-of-day infusion on survival and immunologic correlates in patients with metastatic renal cell carcinoma: a multicenter cohort analysis by Haydn Kissick, Viraj A Master, Mehmet A Bilen, Zachary S Buchwald, Mohammad K Khan, Caroline S Jansen, Michael C Lowe, Jimmy S Patel, Yena Woo, Amber Draper, Jennifer W Carlisle, Pasquale F Innominato, Francis A Lévi, Layla Dhabaan, David C Qian

Get full text

Novel risk group stratification for metastatic urothelial cancer patients treated with immune checkpoint inhibitors by Julie M. Shabto, Dylan J. Martini, Yuan Liu, Deepak Ravindranathan, Jacqueline Brown, Emilie E. Hitron, Greta A. Russler, Sarah Caulfield, Haydn Kissick, Mehrdad Alemozaffar, Kenneth Ogan, Wayne B. Harris, Viraj A. Master, Omer Kucuk, Bradley C. Carthon, Mehmet A. Bilen

Get full text

Treatment-free survival outcomes from the phase II study of nivolumab and salvage nivolumab/ipilimumab in advanced clear cell renal cell carcinoma (HCRN GU16-260-Cohort A) by Michael Hurwitz, Mark Stein, Jeffrey Sosman, David F McDermott, Michael B Atkins, Naomi B Haas, Elizabeth R Plimack, Hans Hammers, Mehmet A Bilen, Meredith M Regan, Moshe C Ornstein, David Einstein, Opeyemi A Jegede, Robert Alter, David J Peace, Paul J Catalano

Get full text

PSCA-targeted BPX-601 CAR T cells with pharmacological activation by rimiducid in metastatic pancreatic and prostate cancer: a phase 1 dose escalation trial by Mark N. Stein, Ecaterina E. Dumbrava, Benjamin A. Teply, Usama S. Gergis, Martin E. Guiterrez, Ran Reshef, Sumit K. Subudhi, Céline F. Jacquemont, Joseph H. Senesac, J. Henri Bayle, Charity D. Scripture, Monica S. Chatwal, Mehmet A. Bilen, Walter M. Stadler, Carlos R. Becerra

Get full text

Blood-based tumor mutational burden impacts clinical outcomes of immune checkpoint inhibitor treated breast and prostate cancers by Reagan M. Barnett, Albert Jang, Sree Lanka, PIngfu Fu, Leslie A. Bucheit, Hani Babiker, Alan Bryce, Haley M. Meyer, Yujin Choi, Casey Moore, Rohan Garje, Xin Gao, Dae Won Kim, Richard Y. Chang, Pat Gulhati, Ryne Ramaker, Rani Bansal, Tian Zhang, A. Oliver Sartor, Andrew J. Armstrong, Mehmet A. Bilen, Pedro Barata

Get full text